Medical Group of North County
Welcome,         Profile    Billing    Logout  
 6 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bessudo, Alberto
BETA-PRIME, NCT04673942: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Recruiting
2
140
US
AdAPT-001, Checkpoint Inhibitor, Immune
EpicentRx, Inc.
Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
12/25
03/27
ARIA, NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Calendar Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Withdrawn
1b/2
156
US
Tazemetostat, IPN60200, Tafasitamab, Lenalidomide, Acalabrutinib, Bruton tyrosine kinase inhibitor, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Epizyme, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
07/23
07/23
NCT04060394: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Active, not recruiting
1/2
74
US, RoW
Phase I and Phase II: LAE001/prednisone + afuresertib, Phase II: Afuresertib
Laekna Limited
Metastatic Castration-resistant Prostate Cancer
12/23
10/24
NCT04180371 / 2019-003653-29: Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Recruiting
1/2
288
Europe, US, RoW
BT5528, Nivolumab, Opdivo
BicycleTx Limited
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
12/23
12/24
NCT04896697: XTX101 Monotherapy and XTX101 and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1/2
96
US
XTX101, Atezolizumab
Xilio Development, Inc., Hoffmann-La Roche
Advanced Solid Tumor
03/26
03/26
NCT05287399: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Recruiting
1
16
US
ASC61 200 mg 1, ASC61 200 mg 2, ASC61 300 mg, ASC61 400 mg, ASC61 600 mg
Gannex Pharma Co., Ltd., Ascletis Pharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/24
12/24
I-RUX-15-04, NCT03110822: A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Checkmark Data from I-RUX study for R/R multiple myeloma
Dec 2022 - Dec 2022: Data from I-RUX study for R/R multiple myeloma
Recruiting
1
134
US
Ruxolitinib Oral Tablet [Jakafi], Ruxolitinib, Jakavi, Lenalidomide, Revlimid, Methylprednisolone, Depo-Medrol, Solu-Medrol, Methyl Prednisolonate
Oncotherapeutics, Incyte Corporation
Multiple Myeloma
09/24
02/27
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Recruiting
1
42
US
HBI-2376
HUYABIO International, LLC.
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
12/24
12/24
NCT05485974: A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Recruiting
1
44
US
HBI-2438
HUYABIO International, LLC.
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
08/25
08/25

Download Options